Today: 7 February 2026
Subscribe
Browse Category

Medical Technology News 9 October 2025 - 30 November 2025

Medtronic (MDT) Stock Near 52‑Week High as Truist Hikes Target and Norges Bank Buys Big

Medtronic (MDT) Stock Near 52‑Week High as Truist Hikes Target and Norges Bank Buys Big

Medtronic plc (NYSE: MDT) is back in the spotlight on 29 November 2025, with its stock trading close to record levels after a strong earnings beat, a fresh wave of analyst updates and sizeable moves from some of the world’s biggest institutional investors. Below is a deep dive into what’s moving Medtronic stock today, and what it could mean for investors watching MDT on Google News and Discover. Snapshot: Where Medtronic Stock Stands Now As of the latest close on 28 November 2025, Medtronic shares trade around $105.33, giving the company a market capitalization of roughly $135 billion.Stock Titan+2Macrotrends+2 Key
30 November 2025
·····
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact Sciences, and a safety correction affecting millions of Libre 3 glucose sensors, all against the backdrop of solid earnings and a long dividend-growth history. Investing.com India+3markets.businessinsider.com+3Stock Titan+3 With a market capitalization above $220 billion and membership in the S&P 500 Dividend Aristocrats index, Abbott remains a core holding for many income and healthcare-focused investors, meaning even relatively small headlines –
26 November 2025
·····
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2 The move marks Abbott’s largest acquisition in nearly a decade and one of the biggest healthcare deals of 2025, instantly positioning the company as a heavyweight in cancer screening and precision oncology diagnostics — markets it has largely approached from the sidelines until now. Reuters+1 As of mid‑afternoon trading, ABT
20 November 2025
······
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will
20 November 2025
······
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market.Bloomberg+1 Abbott in Talks for Biggest Deal in Nearly a Decade On Wednesday, November 19, 2025, multiple outlets reported that Abbott Laboratories is close to a deal to buy Exact Sciences Corp., a U.S.-based molecular diagnostics company best known for its Cologuard colorectal cancer screening test. Bloomberg+1 According to people familiar with the matter cited by Bloomberg, Abbott is negotiating the terms of a transaction with
19 November 2025
····
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook – November 19, 2025

Boston Scientific Corporation (NYSE: BSX) shares traded lower on Wednesday, November 19, 2025, even as a wave of fresh research, strategic partnership news and institutional ownership updates painted a largely constructive long‑term picture for the medtech giant. BSX stock price on 19 November 2025 As of late Wednesday trading, Boston Scientific stock was changing hands at around $96.6, down roughly 2.6% on the day. Intraday, BSX has traded in a range of roughly $96–$100, with volume running in the high single‑digit millions of shares.Investing.com Recent price action shows a short losing streak: BSX closed at about $99.2 on Tuesday (‑2.5%),
19 November 2025
····
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Stock Performance & Trading Trends (2025) ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over $19 by February 2025nasdaq.com. After a mid-year breather, momentum returned in Q3/Q4 2025: the stock surged nearly 40% in one day on September 24, 2025 after announcing an FDA clearance (for its Prism laser) and bullish revenue guidancenasdaq.comnasdaq.com. By late
3 November 2025
···
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic (same-currency) revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices. Analysts highlighted that every major segment beat. The cardiovascular
22 October 2025
····
Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical’s da Vinci surgical robot in an operating room setting. Intuitive’s stock jumped on Oct. 21 after the company reported blowout Q3 results and raised full-year guidance reuters.com ts2.tech. The quarter’s 23% revenue growth was driven by a surge in robot-assisted procedures, as hospitals resume elective surgeries and expand minimally-invasive care reuters.com reuters.com. Reuters notes Intuitive has seen “steady growth as hospitals work through a backlog of deferred procedures” reuters.com, reflecting post-pandemic catch-up demand. Intuitive’s CEO Dave Rosa celebrated the results. He noted “continued growth in customer use and adoption of our Ion and da Vinci platforms, including da
22 October 2025
····
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital
19 October 2025
····
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com. Symphony’s first target analyte is interleukin-6 (IL-6), an inflammatory marker that rises during infection and sepsis. In hospitals today, diagnosing sepsis early
9 October 2025
····
MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

Ottobock’s Blockbuster Debut in Frankfurt Ottobock’s IPO made headlines as the prosthetics manufacturer delivered a much-needed jolt to Germany’s capital market. Trading in Ottobock shares began on October 9, 2025, on the Frankfurt Stock Exchange’s Prime Standard segment. The stock’s first trade at €72.00 was significantly above the €66 per share offering pricedeutsche-boerse.com. That opening price equated to about a +9% “pop” for IPO investors, underscoring the high demand for the shares. In fact, Ottobock’s debut is being celebrated as “the country’s largest IPO in over a year”, according to Reutersglobalbankingandfinance.com. It’s a standout given the recent scarcity of large offerings in Frankfurt. The initial valuation of the
9 October 2025
····
1 … 3 4 5 6

Stock Market Today

CrowdStrike stock jumps nearly 5% after Aramco pact — what investors watch next

CrowdStrike stock jumps nearly 5% after Aramco pact — what investors watch next

7 February 2026
CrowdStrike shares jumped 4.8% to $395.50 after the company announced a non-binding memorandum of understanding with Saudi Aramco. The move ended a seven-session losing streak for the stock, which remains about 30% below its 52-week high. Investors await more details on the Aramco talks and CrowdStrike’s March 3 earnings report. Trading volume topped 4.9 million shares, well above average.
Visa stock price edges up as Visa & Main rolls out — what’s next for NYSE:V

Visa stock price edges up as Visa & Main rolls out — what’s next for NYSE:V

7 February 2026
Visa shares closed up 0.74% at $331.58 Friday, holding steady after hours. The company launched “Visa & Main,” a $100 million working-capital facility for small businesses through Lendistry. Investors are watching program adoption and Visa’s Feb. 10 dividend record date. The S&P 500 rose 1.97% and American Express gained 1.28%.
Spotify stock rebounds after-hours as Bookshop.org move and new features tee up Q4 earnings

Spotify stock rebounds after-hours as Bookshop.org move and new features tee up Q4 earnings

7 February 2026
Spotify shares rose 2.4% in late after-hours trading Friday, closing at $422.61. The company this week announced U.S. and U.K. users can order physical books via Bookshop.org in-app, and introduced new audiobook and music features. Spotify raised Premium prices by $1 in select markets, sending shares down 4.5% Thursday. Investors await Q4 earnings on Feb. 10 for updates on revenue and new product impact.
Go toTop